Eagle Common Stock Total Equity from 2010 to 2026
| EGRX Stock | USD 0.25 0.00 0.00% |
Common Stock Total Equity | First Reported 2013-09-30 | Previous Quarter 18 K | Current Value 18 K | Quarterly Volatility 2.5 K |
Check Eagle Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eagle Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 M, Interest Expense of 4.9 M or Selling General Administrative of 118.5 M, as well as many indicators such as Price To Sales Ratio of 1.3, Dividend Yield of 0.0 or PTB Ratio of 1.77. Eagle financial statements analysis is a perfect complement when working with Eagle Pharmaceuticals Valuation or Volatility modules.
Eagle | Common Stock Total Equity | Build AI portfolio with Eagle Stock |
The evolution of Common Stock Total Equity for Eagle Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Eagle Pharmaceuticals compares to historical norms and industry peers.
Latest Eagle Pharmaceuticals' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Eagle Pharmaceuticals over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Eagle Pharmaceuticals' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eagle Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Eagle Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 13,346 | |
| Geometric Mean | 10,073 | |
| Coefficient Of Variation | 49.89 | |
| Mean Deviation | 5,338 | |
| Median | 16,000 | |
| Standard Deviation | 6,658 | |
| Sample Variance | 44.3M | |
| Range | 19K | |
| R-Value | 0.82 | |
| Mean Square Error | 15.8M | |
| R-Squared | 0.67 | |
| Significance | 0.000063 | |
| Slope | 1,077 | |
| Total Sum of Squares | 709.3M |
Eagle Common Stock Total Equity History
About Eagle Pharmaceuticals Financial Statements
Eagle Pharmaceuticals investors use historical fundamental indicators, such as Eagle Pharmaceuticals' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eagle Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 20.7 K | 15.2 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eagle Stock Analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.